David Mowry - Cutera CEO, Director
| CUTR Stock | USD 0.48 0.02 3.61% |
CEO
Mr. David H. Mowry is Chief Executive Officer, Director of the Company. Mr. Mowry is a career medical device executive with successful leadership assignments across multiple market segments. Most recently, Mr. Mowry served as President and CEO of Vyaire Medical, a privatelyheld global respiratory care business with revenues exceeding 750mm. While serving at Vyaire, Mr. Mowry led the efforts to carveout four separate divisions from BectonDickinson and Company, following its acquisition of CareFusion, combining the units into a standalone, singularlyfocused Respiratory Care company. Prior to Vyaire, Mr. Mowry was the President and CEO of Tornier Inc., a publiclytraded leader in orthopedic extremities solutions acquired by Wright Medical in October 2015 for approximately 1.6 billion. While leading Tornier, Mr. Mowry consistently delivered abovemarket growth through strong commercial execution, portfolio development and differentiated service to Tornier clinician customers. Prior to Tornier, Mr. Mowry served as President of Covidien Neurovascular Division, a recognized leader in the hemorrhagic and ischemic stroke interventional device markets since 2019.
| Age | 62 |
| Tenure | 5 years |
| Address | 3240 Bayshore Boulevard, Brisbane, CA, United States, 94005-1021 |
| Phone | (415) 657-5500 |
| Web | https://www.cutera.com |
Cutera Management Efficiency
The company has return on total asset (ROA) of (0.2581) % which means that it has lost $0.2581 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (44.4726) %, meaning that it created substantial loss on money invested by shareholders. Cutera's management efficiency ratios could be used to measure how well Cutera manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Equity is likely to grow to 1.00, though Return On Tangible Assets are likely to grow to (0.45). At this time, Cutera's Total Assets are relatively stable compared to the past year. As of 11/29/2024, Total Current Assets is likely to grow to about 282.6 M, while Intangible Assets are likely to drop slightly above 1.1 M.Similar Executives
| Found 14 records | CEO Age | ||
| Massimo Calafiore | Orthofix Medical | 52 | |
| Damien McDonald | LivaNova PLC | 59 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
| Gary Maharaj | SurModics | 61 | |
| Joel Becker | Neuropace | 56 | |
| Mark Throdahl | Orthopediatrics Corp | 73 | |
| Nadim Yared | CVRx Inc | 56 | |
| Charles II | Apyx Medical | 58 | |
| Kevin Hykes | CVRx Inc | 58 | |
| Steven Williamson | Pulmonx Corp | 51 | |
| Glendon French | Pulmonx Corp | 62 | |
| Vladimir Makatsaria | LivaNova PLC | 51 | |
| Albert DaCosta | Paragon 28 | 51 | |
| Kathleen Skarvan | Electromed | 68 | |
Management Performance
| Return On Equity | -44.47 | ||||
| Return On Asset | -0.26 |
Cutera Inc Leadership Team
Elected by the shareholders, the Cutera's board of directors comprises two types of representatives: Cutera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cutera. The board's role is to monitor Cutera's management team and ensure that shareholders' interests are well served. Cutera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cutera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Plants, Independent Director | ||
| Taylor Harris, CEO President | ||
| David Mowry, CEO, Director | ||
| Rohan Seth, Chief Officer | ||
| Sheila Hopkins, Consultant | ||
| Anne Werdan, Director Relations | ||
| Steve Kreider, Senior Marketing | ||
| Brent Hauser, President International | ||
| Shelby Eckerman, Vice Finance | ||
| Michael Karavitis, Executive Vice President CTO | ||
| Greg Barker, Vice Relations | ||
| Charles Thier, Chief Officer | ||
| Dr JD, Chief Officer | ||
| Stuart Drummond, Interim Officer | ||
| Jeffrey Jones, Chief Officer |
Cutera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cutera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -44.47 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.93) % | ||||
| Operating Margin | (1.11) % | ||||
| Current Valuation | 383.82 M | ||||
| Shares Outstanding | 20.19 M | ||||
| Shares Owned By Insiders | 1.98 % | ||||
| Shares Owned By Institutions | 37.45 % | ||||
| Number Of Shares Shorted | 4.04 M | ||||
| Price To Earning | 116.17 X |
Pair Trading with Cutera
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cutera position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cutera will appreciate offsetting losses from the drop in the long position's value.Moving against Cutera Stock
| 0.85 | VREX | Varex Imaging Corp | PairCorr |
| 0.85 | ELMD | Electromed | PairCorr |
| 0.81 | MD | Mednax Inc | PairCorr |
| 0.79 | LH | Laboratory | PairCorr |
| 0.79 | OM | Outset Medical | PairCorr |
The ability to find closely correlated positions to Cutera could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cutera when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cutera - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cutera Inc to buy it.
The correlation of Cutera is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cutera moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cutera Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cutera can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cutera Stock Analysis
When running Cutera's price analysis, check to measure Cutera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cutera is operating at the current time. Most of Cutera's value examination focuses on studying past and present price action to predict the probability of Cutera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cutera's price. Additionally, you may evaluate how the addition of Cutera to your portfolios can decrease your overall portfolio volatility.